New stocks and HK stocks are all in the red 😇
HSI Settles Lower by 640 pts as Financials Blown; HSBC HOLDINGS Slips 5% Below HKD150
AIA Group Limited, together with its subsidiaries, provides life insurance based financial services in Hong Kong. The company offers life insurance, accident, a...
AIA closed at HK$78.30 today, up 0.71%, showing a pattern of morning strength followed by afternoon weakness—the stock surged to HK$79.45 at 10:06 AM before pulling back to an intraday low of HK$78.00 later in the afternoon, finally settling near midday levels. This volatility mirrors recent market dynamics: UBS confirmed the company's multi-currency business returned to growth in August-September, while Morgan Stanley maintained its overweight rating and deemed the 5% decline in Q3 new business value in line with expectations, driving initial buying interest that faded into profit-taking. On the earnings front, Q2 net profit surged 69.3% year-over-year, with EPS of HK$1.6129 and ROE of 21.1%, demonstrating robust earnings power. Valuation-wise, the current PE of 12.9x is trading at a discount, yet the stock remains down 15% from its 52-week high of HK$92.15 and has declined 6% year-to-date, reflecting persistent market concerns over challenges in Hong Kong and Mainland China operations.
AIA fell 1.9% to HKD 77.75 today as market risk aversion intensified with the Hang Seng Index breaking below 24,000 and AI semiconductor stocks facing steep declines. Intraday weakness accelerated, with morning session closing at HKD 78.30 before afternoon trading dipped to a daily low of HKD 76.95, signaling ebbing buy interest. The company's third-quarter new business value declined 5% year-over-year, with Hong Kong and mainland China operations showing notable weakness, serving as a direct negative catalyst. However, earnings resilience continues, with Q1 and Q2 2026 EPS both reaching HKD 1.61, up over 72% year-over-year and net profit surging over 70%, maintaining ROE above 20%, demonstrating solid underlying profitability. The stock trades above its 20 and 60-day moving averages (HKD 75.04 and HKD 74.59 respectively) but remains 15.6% below its 52-week high of HKD 92.15, declining 6.66% year-to-date. With a PE of 12.83x, PB of 2.52x, and dividend yield of 2.57%, valuation appears moderate.
Stock surged during afternoon trading, opening at HKD 78.10 before rallying to HKD 79.35 around 14:58 Beijing time and closing at HKD 79.25, a 0.44% gain from previous close. The advance reflects renewed confidence in AIA's growth outlook. Though Q3 VONB declined 5% year-over-year, cumulative 1-3Q VONB grew 5% and nine-month NBV expanded 5%, signaling stabilization in momentum. UBS highlighted that AIA's MCV business returned to growth in August-September, alleviating investor concerns. Earnings underscores the positive narrative: Q1 and Q2 EPS surged 72-74% year-over-year, net profit jumped around 70%, and ROE remained above 20%, demonstrating strong profitability. Current price of HKD 79.25 trades notably above the 60-day moving average of 74.51, holding 14% upside potential toward the 52-week high of 92.15. However, year-to-date the stock has declined 4.86%, and operating revenue contracted 1.71-2.55% year-over-year, reflecting structural pressures on insurance business growth despite strong bottom-line gains.
AIA Group declined marginally by around 0.6% today, rising to an intraday peak of HK$79.4 in the morning session but retreating to HK$78.9 by close, reflecting profit-taking after recent consecutive gains. Third-quarter results showed new business value contracted 5% year-over-year, with Hong Kong and mainland markets as key headwinds, though nine-month cumulative VONB still expanded 5%, and UBS recently noted the company's mainstream medical and health business has returned to growth. Recent quarters show robust EPS growth exceeding 70% year-over-year with net profit rising approximately 70% despite flat revenue, while ROE remained stable above 20%. Valuation-wise, P/E stands at merely 13x, appearing reasonable. On price positioning, the stock is down 5.28% year-to-date and 14.38% from its 52-week high, yet trades well above both 20-day and 60-day moving averages. Market consensus target price sits above the current level, though structural challenges in the mainland market warrant continued monitoring.
AIA gained 1.0% to close at HKD 79.35 with 20.01 million shares traded. Morning session opened at 79.90 at 09:30, dipped to 78.70 low at 10:08; afternoon session recovered to 79.00 at 13:00, touched 79.45 high at 15:42, and closed at 79.35 at 16:00. Recent weakness stemmed from 3Q new business value declining 5%, weighing on Hong Kong and Mainland China business outlook, yet MCV business returned to growth in August-September suggesting potential bottoming. Valuations remain attractive with PE at 13.1x and PB at 2.57x, while EPS stayed robust at around HKD 1.61 over recent quarters with over 70% YoY growth. Brand recognition topped Singapore's most-considered insurance market ranking, with analyst consensus maintaining overweight and target price above current spot. YTD performance declined 4.74% from year-start, trading 13.89% below the 52-week high of HKD 92.15, reflecting market caution on sustaining growth momentum.
Weekly Recap | AIA -1.02%, regional business recovery
Yida China Reports October Contracted Sales of Approximately RMB 11 Million
AIA tops Singapore's most considered insurance brand: YouGov
UBS: AIA MCV Biz Returns to Growth in Aug-Sep
HSBC Research Upgrades HKEX to Buy as Risk-Reward of Greater China Financial Stocks Shifts
Weekly Recap | AIA +4.05%, consensus target above spot
New stocks and HK stocks are all in the red 😇
HSI Settles Lower by 640 pts as Financials Blown; HSBC HOLDINGS Slips 5% Below HKD150
Hong Kong stocks are in a sea of red, dizzying 😵
HSI Settles Lower by 640 pts as Financials Blown; HSBC HOLDINGS Slips 5% Below HKD150
The 3 local banks have stabilised a little following the previous few days of down sessions for the whole SG market. This is good for the longer scheme of things as historical statistics show that steep rise s n share prices are more likely than not followed by steep drawbacks afterwards. Let them consolidate, though I know many are still buying either for long term or just trying to jump on bandwagon.
Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...
